PHASE I CLINICAL TRIAL OF 17-ALLYLAMINO-17-DEMETHOXY-GELDANAMYCIN (KOS-953)

17-烯丙氨基-17-去甲氧基格尔德霉素 (KOS-953) 的 I 期临床试验

• 批准号: 7603888
• 负责人: AMRITA KRISHNAN
• 金额: $ 0.1万
• 依托单位: UNIVERSITY OF SOUTHERN CALIFORNIA
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-12-01 至 2007-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7603888
• 关键词: 17-(Allylamino)-17-demethoxygeldanamycin; Bortezomib; Computer Retrieval of Information on Scientific Projects Database; Dose; Funding; Geldanamycin; Grant; Institution; Label; Multiple Myeloma; Patients; Phase; Phase I Clinical Trials; Refractory; Relapse; Research; Research Personnel; Resources; Source; United States National Institutes of Health; Week; day

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Phase I, open-label, dose excalating trial in patients with advanced multiple myeloma. The primary objective is to determine the MTD of KOS-953 (17-AAG) when administered in combination with bortezomib (BZ) to patients with relapsed or relapsed/refractory multiple myeloma on Day 1, 4 8 and 11 every three weeks.

这个子项目是众多研究子项目之一